New blood tests to evaluate liver cancer treatment response
Novel circulating biomarker digital scores for assessing treatment response in liver cancer
This study is looking at new blood tests to see how well liver cancer treatments are working for patients, helping doctors provide more personalized care based on the results.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10913356 on NIH RePORTER |
What this research studies
This research focuses on developing innovative blood tests that can help assess how well patients with liver cancer are responding to their treatments. By utilizing advanced liquid biopsy technologies, the study aims to identify specific biomarkers that indicate treatment effectiveness and cancer progression. Patients will be monitored over time to gather data that can improve the accuracy of treatment evaluations, ultimately leading to more personalized care. The research also emphasizes the importance of understanding the biological behavior of liver cancer to enhance patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with hepatocellular carcinoma (HCC) who are undergoing treatment.
Not a fit: Patients with liver cancer who are not receiving treatment or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and timely assessments of treatment responses in liver cancer patients, improving their overall care.
How similar studies have performed: Previous research has shown promise in using liquid biopsies for cancer monitoring, indicating that this approach could be effective for liver cancer as well.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Yang, Ju Dong — Cedars-Sinai Medical Center
- Study coordinator: Yang, Ju Dong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.